You can't treat what you don't test: implementation of lipoprotein(a) testing and evidence-based treatment plan for midlife women in a wellness clinic

Abstract

Background: Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) when present in elevated levels (>50 mg/dL) and existing in 20-30% of the general population, yet fewer than 1% of U.S. adults have ever been screened. Lp(a) accelerates arterial plaque formation at six times the rate of a typical LDL particle and is 70-90% genetically determined, though hormonally modulated. Lp(a) demonstrates an inverse relationship with estrogen, such that supplementation after ovarian failure may lower concentrations by up to 30%--representing a relationship of particular relevance for midlife women, whose progressive estrogen decline eliminates endogenous arterial protection and accelerates ASCVD risk, particularly when baseline Lp(a) is already elevated. Purpose: This quality improvement project implemented standardized Lp(a) screening and individualized, evidence-based treatment planning in a wellness clinic primarily serving peri- and menopausal women receiving bioidentical hormone replacement therapy. Methods: Grounded in the Johns Hopkins Evidence-Based Practice Model and guided by iterative Plan-Do-Study-Act cycles, Lp(a) testing was integrated into the clinic's existing laboratory order set over eight weeks. Patients with Lp(a) >50 mg/dL received individualized education addressing diet, physical activity, supplementation, hormonal optimization, and self-advocacy for further risk stratification. Results: All 17 eligible patients were screened (100%; exceeding the 90% SMARTIE target) and all four patients with Lp(a) >50mg/dL received education (100%; meeting 100% SMARTIE target), plus one additional patient with a borderline elevation of 41.1mg/dL, consistent with the testing laboratory's flagging threshold of >30mg/dL. The sample was predominantly female (70.6%; M age = 44.6 years). Lp(a) was right-skewed (Mdn = 11.3 mg/dL; IQR: 8.3 - 41.1), with no statistically significant correlations observed between Lp(a) and other biomarkers, reinforcing the particle's independent metabolic pathway from other lipids. Conclusion: Routine Lp(a) screening is feasible and clinically meaningful in hormone management settings. A 23.5% prevalence among eligible patients (consistent with general population-level findings) underscores the urgency of universal screening and offers a replicable integration model.